• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Hybrid immunity protects against infection with omicron variant of COVID-19

byDavid XiangandKiera Liblik
July 7, 2022
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Previous infection, vaccination, and hybrid immunity protected against infection with the omicron variant of coronavirus disease 2019 (COVID-19).

2. Hybrid immunity from previous infection and recent booster vaccination provided the strongest overall protection against the omicron variant.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The omicron variant of SARS-CoV-2 was prevalent from late 2021 into early 2022. It was dominated by the BA.1 subvariant and the BA.2 subvariant. However, the degree of protection against these subvariants provided by previous immunity is uncertain. Furthermore, whether the strongest immunity is induced by previous infection, vaccination, or a hybrid, is also unclear. Therefore, there is a gap in knowledge as to understanding whether protection against omicron infection exists and whether there are differences in immunity conferred via previous infection, vaccination, or a hybrid of both. Overall, this study found that there were no notable differences in effectiveness against omicron of previous infection, vaccination, and hybrid immunity, and all provided strong protection against COVID-19-related hospitalization and death. This study was limited by unexpected biases such as subtle differences or changes in test-seeking behavior, as well as the study population not being generalizable to other countries in which elderly citizens make up a larger proportion of the population. Nevertheless, the study’s findings are significant, as they demonstrate that protection against omicron occurs via previous infection, vaccination, and hybrid immunity, and that hybrid immunity provided the strongest overall protection against infection.

Click to read the study in NEJM

Relevant Reading: Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant

In-Depth [case-control study]: The present study was conducted in Qatar, based on cases of COVID-19 identified from December 2021 through February 2022. Case participants and controls were matched according to sex, 10-year age group, nationality, and week of PCR test. Patients who had COVID-19 tests that occurred within 14 days after the second dose of a COVID-19 vaccination or seven days after the third dose were excluded from the study. The primary outcome was COVID-19 infection based on a positive PCR test. The classification of severe, critical, and fatal COVID-19 cases was based on World Health Organization guidelines. Outcomes in the primary analysis were assessed via frequency distributions and measures of central tendency and compared with the use of standardized mean differences. Based on the primary analysis, the effectiveness of previous infection alone against symptomatic omicron infection was 46.1% (95% Confidence Interval [CI], 39.6 to 51.9). Having received two doses of BNT162b2 vaccination conferred similar effectiveness against symptomatic omicron infection (-1.1%; 95% CI, -7.1 to 4.6). Furthermore, having received three doses of BNT162b2 vaccination had an effectiveness against symptomatic omicron infection of 52.2% (95% CI, 48.1 to 55.9). The effectiveness of previous infection with two doses of BNT162b2 was 55.1% (95% CI, 50.8 to 58.9). Finally,  the effectiveness of previous infection and three doses of BNT162b2 was the highest among all possible immunity groups, with an effectiveness of 77.3% (95% CI, 72.4 to 81.4). Previous infection alone, vaccination alone, and hybrid immunity all conferred strong effectiveness against severe, critical, or fatal COVID-19 due to omicron. Overall, this study showed that there were no significant differences in protection against omicron infection with previous infection, vaccination, or hybrid immunity, though hybrid immunity does offer the strongest protection.

RELATED REPORTS

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

2 Minute Medicine Rewind January 23, 2023

Unvaccinated status increases risk of long COVID symptoms

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID-19Hybrid ImmunityImmunityinfectious diseaseomicronpublic healthSARS-CoV-2vaccination
Previous Post

#VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity

Next Post

Life expectancy disparities have increased between ethnic groups in certain states

RelatedReports

Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
School nurses essential in design and implementation of school safety programs
Chronic Disease

Combined visual-olfactory training for COVID-19 resultant olfactory loss

January 23, 2023
Next Post
Institute of Medicine identifies cost variation between geographic regions

Life expectancy disparities have increased between ethnic groups in certain states

Brain lesions on MRI linked with subsequent increased stroke risk

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

Novel coronavirus identified from patients with pneumonia in Wuhan, China

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options